Ackman’s London-Listed Pershing Square Gets Its Own Activist (Bloomberg) Bill Ackman’s publicly-traded Pershing Square Holdings Ltd. has an activist...
Keep Reading →
July 16 - Hedge Funds, Insider Trading - Comments
Peter Kolchinsky’s RA Capital purchased $20 million of Kala Pharmaceuticals Inc. (KALA) shares. The details of the transaction can be seen below...
Keep Reading →
October 8 - Hedge Funds, Insider Trading, News - Comments
Peter Kolchinsky is one of the best biotech investors and many of his stock picks generate strong returns. We calculate a fund’s returns by taking...
Keep Reading →
June 12 - Hedge Funds, News - Comments
Biotechnology is a very interesting industry to invest in, but also very complex. If you are looking for stocks that are most likely to see their value...
Keep Reading →
May 1 - Hedge Funds, News - Comments
Biocryst Pharmaceuticals Inc (NASDAQ:BCRX): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management...
Keep Reading →
April 3 - Hedge Funds - Comments
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management...
Keep Reading →
March 28 - Hedge Funds - Comments
Solid Biosciences Inc (NASDAQ:SLDB): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management’...
Keep Reading →
February 12 - Hedge Funds - Comments
With the stock market having been battered in recent days and fears that a large correction may be starting to pick up steam becoming more pronounced,...
Keep Reading →
February 5 - Hedge Funds, Insider Trading, Market Movers, News - Comments
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management...
Keep Reading →
January 26 - Hedge Funds - Comments
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management...
Keep Reading →
December 22 - Hedge Funds - Comments
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management...
Keep Reading →
December 18 - Hedge Funds - Comments
Scpharmaceuticals Inc (NASDAQ:SCPH): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management’...
Keep Reading →
December 12 - Hedge Funds - Comments
Inflarx NV (NASDAQ:IFRX): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management’s latest...
Keep Reading →
December 12 - Hedge Funds - Comments
Wave Life Sciences Ltd (NASDAQ:WVE): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management’...
Keep Reading →
November 20 - Hedge Funds - Comments
Sunesis Pharmaceuticals Inc (NASDAQ:SNSS): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management...
Keep Reading →
November 14 - Hedge Funds - Comments
Kalvista Pharmaceuticals Inc. (NASDAQ:KALV): Peter Kolchinsky’s RA Capital Management filed an amended 13D. You can check out RA Capital Management...
Keep Reading →
November 14 - Hedge Funds - Comments
You can access the original SEC filing by clicking here. Ownership Summary Table Page 1 of 9 – SEC Filing UNITED STATES SECURITIES AND EXCHANGE...
Keep Reading →
April 13 - Hedge Funds - Comments
Peter Kolchinsky‘s RA Capital Management has slightly raised its stake in Avexis Inc. (NASDAQ:AVXS), as per a new Form 13G with the Securities...
Keep Reading →
December 27 - Hedge Funds, News - Comments
Peter Kolchinsky‘s RA Capital Management has slashed its position in Alcobra Ltd (NASDAQ:ADHD) to just under 1.31 million shares according to a...
Keep Reading →
October 23 - Hedge Funds, News - Comments
An amended 13G filing with the SEC revealed that Peter Kolchinsky‘s RA Capital Management has sold around 1.1 million shares of Aclaris Therapeutics...
Keep Reading →
October 7 - Hedge Funds, News - Comments
Peter Kolchinsky‘s RA Capital Management reported via a recent 13G filing with the SEC that it has taken a new position in a company that has recently...
Keep Reading →
August 26 - Hedge Funds, News - Comments
A recent 13G filing with the SEC revealed that Peter Kolchinsky‘s RA Capital Management has acquired more shares of Vitae Pharmaceuticals Inc...
Keep Reading →
August 16 - Hedge Funds, News - Comments
Peter Kolchinsky‘s RA Capital Management has stepped up its interest in Ardelyx Inc. (NASDAQ:ARDX). As reported in a recent filing with the Securities...
Keep Reading →
July 29 - Hedge Funds, News - Comments
Peter Kolchinsky founded RA Capital Management in 2001 and focuses mainly on healthcare stocks. One of the few hedge fund managers who actually holds...
Keep Reading →
February 25 - Hedge Funds, News - Comments
In a new filing with the Securities and Exchange Commission, Peter Kolchinsky‘s RA Capital Management disclosed a position in Derma Sciences Inc...
Keep Reading →
February 1 - Hedge Funds, News - Comments
The practice of monitoring quarterly 13F filings has become more popular in recent years, which led to several exchange traded funds (ETFs) being launched...
Keep Reading →
November 30 - Hedge Fund Analysis, Hedge Funds, News - Comments
With hedge funds having submitted their 13F filings for the third quarter, people at Insider Monkey are busy compiling the data necessary to identify...
Keep Reading →
November 20 - Hedge Funds, News - Comments
Three prominent healthcare-focused funds that we track at Insider Monkey submitted filings with the SEC today, disclosing new or bulked up positions in...
Keep Reading →
October 13 - Hedge Funds, News - Comments
RA Capital Management, led by Peter Kolchinsky, has disclosed a massive new stake in California-based pharmaceutical company Zogenix, Inc (NASDAQ:ZGNX...
Keep Reading →
October 9 - Hedge Funds, News - Comments
Steve Cohen’s Point72 Asset Management has initiated a new position in Inotek Pharmaceuticals Corporation (NASDAQ:ITEK). In a freshly-submitted filing...
Keep Reading →
August 25 - Hedge Funds, News - Comments
Peter Kolchinsky‘s RA Capital Management recently filed its 13F with the SEC for the reporting period of June 30. Peter Kolchinsky started RA Capital...
Keep Reading →
August 15 - Hedge Fund Analysis, Hedge Funds, News - Comments
RA Capital Management, led by Peter Kolchinsky, has opened a new position in clinical-stage biopharmaceutical company Ardelyx Inc (NASDAQ:ARDX). A new...
Keep Reading →
June 7 - Hedge Funds, News - Comments
In a new filing with the Securities and Exchange Commission, Billionaire Chase Coleman‘s Tiger Global disclosed slightly reducing its exposure...
Keep Reading →
March 27 - Hedge Funds, News, Tech - Comments
Peter Kolchinsky’s RA Capital Management filed its latest 13F with the Securities and Exchange Commission in February, and we’ve gone through the...
Keep Reading →
March 4 - Hedge Funds, News - Comments
Baker Bros. Advisors, the fund managed by Julian and Felix Baker disclosed changes in two of its activist positions last Thursday. The firm continued...
Keep Reading →
December 15 - Hedge Funds, News - Comments
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and Proteon Therapeutics Inc (NASDAQ:PRTO) are in the spotlight as James E. Flynn’s Deerfield Management and...
Keep Reading →
November 3 - Hedge Funds, News - Comments
In two new filings, Thomas E. Claugus‘ GMT Capital disclosed further raising its exposure to Entegris Inc (NASDAQ:ENTG). The investor revealed buying...
Keep Reading →
October 16 - Hedge Funds, News, Tech - Comments
CIG Wireless Corp (OTCBB:CIGW), an operator of wireless and broadcast communication towers in the United States, has issued approximately 1.25 million...
Keep Reading →
October 2 - Hedge Funds, News - Comments
RA Capital Management has continued the sale of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares. In a recent wave of reductions, the fund has dumped...
Keep Reading →
September 29 - Hedge Funds, News - Comments
RA Capital Management, managed by Peter Kolchinsky, continues to unload its stake in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). In a new filing with...
Keep Reading →
September 24 - Hedge Funds, News - Comments
Citadel Advisors, a fund managed by Ken Griffin, has disclosed boosting its stake in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS). Citadel upped its position...
Keep Reading →
September 22 - Hedge Funds, News - Comments
Peter Kolchinsky‘s RA Capital Management, in a new filing with the Securities and Exchange Commission, has disclosed the sale of around 1.70 million...
Keep Reading →
September 12 - Hedge Funds, News - Comments
In a new filing with the U.S. Securities and Exchange Commission, RA Capital Management, managed by Peter Kolchinsky, has disclosed holding an 18.1% passive...
Keep Reading →
September 4 - Hedge Funds, News - Comments
Manchester United Divides Hedge Funds’ Loyalties (WSJ) Some of Europe’s most powerful hedge fund managers are sharply divided on the outlook...
Keep Reading →
August 28 - Hedge Funds - Comments
RA Capital Management, led by Peter Kolchinsky, disclosed in a newly amended filing with the U.S. Securities and Exchange Commission that it further reduced...
Keep Reading →
August 28 - Hedge Funds, News - Comments
Amidst the 13F filing season, several hedge funds have also been filing Schedule 13G forms, disclosing changes that took place after June 30, 2014, in...
Keep Reading →
August 21 - Hedge Funds, News - Comments
Citadel’s Griffin Defends HFT (FINalternatives) Citadel Investment Group founder Kenneth Griffin yesterday urged Congress not to ban high-frequency...
Keep Reading →
July 9 - Hedge Funds - Comments
RA Capital Management, managed by Peter Kolchinsky, has sold 800,000 shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) in two transactions for about...
Keep Reading →
June 25 - Hedge Funds, News - Comments
James H. Litinsky‘s JHL Capital Group has boosted its stake in Ophthotech Corp (NASDAQ:OPHT) to 1.78 million shares, a new filing with the SEC...
Keep Reading →
April 15 - Hedge Funds, News - Comments
Peter Kolchinsky’s RA Capital Management has initiated a new position in Versartis Inc (NASDAQ:VSAR). RA Capital owns 1.40 million shares of the company...
Keep Reading →
April 10 - Hedge Funds, News - Comments
